New siRNA Drugs Show Early Promise in Phase 1/2 Trials
On March 25, Sarepta Therapeutics (NASDAQ:SRPT) announced positive initial results from Phase 1/2 studies for two experimental siRNA drugs, marking a potential breakthrough for its pipeline. The trials for SRP-1001, targeting facioscapulohumeral muscular dystrophy type 1 (FSHD1), and SRP-1003, for myotonic dystrophy type 1 (DM1), both demonstrated dose-dependent muscle exposure and favorable tolerability. These findings represent a crucial first validation of the company's expansion into siRNA-based genetic medicines for rare diseases.
Data Offers Hope After 79% Stock Collapse
The encouraging pipeline update arrives at a critical moment for Sarepta, whose stock has plummeted 79% over the past 12 months. The sharp decline was driven by significant setbacks, including patient deaths linked to liver failure from its key Duchenne muscular dystrophy (DMD) drug, Elevidys. These safety issues damaged investor sentiment and contributed to the company's revenue dropping 33% year-over-year to $442.9 million in the fourth quarter of 2025. The early success of SRP-1001 and SRP-1003 offers a potential new growth avenue to offset challenges within its commercial portfolio.
Analysts Cautious as Regulatory Hurdles Remain
Wall Street remains divided on Sarepta's trajectory, with the analyst consensus rating at a "Hold" with an average price target of $21.28. However, some firms see significant upside, with Mizuho Securities reiterating a "Buy" rating with a $31.00 price target and Oppenheimer maintaining its own "Buy" rating with a $37.00 price target. Investors are also watching the company's efforts to convert accelerated approvals for its other DMD drugs, Amondys 45 and Vyondys 53, to full traditional approvals. This move could strengthen its core franchise but faces uncertainty after confirmatory trials missed their primary endpoints.
